Target Name: LOC105371611
NCBI ID: G105371611
Review Report on LOC105371611 Target / Biomarker Content of Review Report on LOC105371611 Target / Biomarker
LOC105371611
Other Name(s): LOC105371611 variant X2 | Uncharacterized LOC105371611, transcript variant X2 | uncharacterized LOC105371611

LOC105371611: A Potential Drug Target for small molecules

LOC105371611 (LOC105371611 variant X2) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the heat shock protein (HSP) family, which are proteins that are involved in the regulation of protein synthesis and folding in response to increased levels of thermal stress.

LOC105371611 variant X2 is unique because of its ability to interact with small molecules, such as drugs and toxins. This interaction allows it to serve as a drug target or biomarker, as researchers can use techniques such as genetic modification or expression to manipulate its activity and study its effects on various cellular processes.

One of the key challenges in studying LOC105371611 variant X2 as a drug target is its complex structure. The protein is composed of multiple domains, including an N-terminal alpha helix, a middle domain that contains a hydrogen bonding network, and a C-terminal tails that contain multiple conserved secondary structure elements such as alpha-helices and beta-strands.

The N-terminal alpha helix is ??????the protein's most conserved region and is involved in the formation of a hydrogen bonding network that is important for stability and interactions with other proteins. The middle domain is also conserved and contains several key elements that are involved in the formation of a complex network of hydrogen bonds.

The C-terminal tails contain several conserved secondary structure elements that are involved in the protein's stability and interactions with other proteins. These elements include an alpha-helix, a beta-sheet, and a gamma-sheet.

In addition to its conserved domains, LOC105371611 variant X2 also has a unique feature that makes it a potential drug target. The protein has a predicted hydrophobic tail, which is often associated with decreased stability and increased sensitivity to hydrophobic drugs. This feature could make it an attractive target for small molecules that are designed to modulate its activity.

LOC105371611 variant X2 has also been shown to interact with several small molecules, including drugs such as rapamycin and curcumin. Rapamycin is an inhibitor of the mTOR pathway, which is involved in cell growth and survival, and has been shown to interact with LOC105371611 variant to inhibit its activity. Curcumin is a compound that is derived from the turmeric plant, and has been shown to have anti-inflammatory and antioxidant properties.

Research into LOC105371611 variant X2 as a drug target is still in its early stages, but the potential implications are significant. The protein's unique structure and its interaction with small molecules make it an attractive target for drug development, and its conserved domains and hydrophobic tail suggest that it may be a good candidate for compounds that modulate its activity. Further research is needed to fully understand the protein's role in cellular processes and its potential as a drug target.

Protein Name: Uncharacterized LOC105371611

The "LOC105371611 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105371611 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC105371614 | LOC105371642 | LOC105371649 | LOC105371655 | LOC105371661 | LOC105371664 | LOC105371665 | LOC105371671 | LOC105371675 | LOC105371692 | LOC105371701 | LOC105371702 | LOC105371719 | LOC105371720 | LOC105371730 | LOC105371744 | LOC105371749 | LOC105371767 | LOC105371770 | LOC105371773 | LOC105371775 | LOC105371776 | LOC105371793 | LOC105371800 | LOC105371801 | LOC105371814 | LOC105371829 | LOC105371839 | LOC105371855 | LOC105371870 | LOC105371873 | LOC105371874 | LOC105371887 | LOC105371910 | LOC105371920 | LOC105371956 | LOC105371958 | LOC105371965 | LOC105371967 | LOC105371972 | LOC105372028 | LOC105372046 | LOC105372047 | LOC105372061 | LOC105372093 | LOC105372100 | LOC105372101 | LOC105372112 | LOC105372117 | LOC105372130 | LOC105372131 | LOC105372146 | LOC105372153 | LOC105372155 | LOC105372161 | LOC105372178 | LOC105372185 | LOC105372194 | LOC105372213 | LOC105372221 | LOC105372225 | LOC105372227 | LOC105372283 | LOC105372298 | LOC105372321 | LOC105372326 | LOC105372327 | LOC105372328 | LOC105372343 | LOC105372351 | LOC105372354 | LOC105372371 | LOC105372379 | LOC105372400 | LOC105372401 | LOC105372427 | LOC105372441 | LOC105372460 | LOC105372502 | LOC105372503 | LOC105372505 | LOC105372507 | LOC105372511 | LOC105372521 | LOC105372529 | LOC105372548 | LOC105372561 | LOC105372577 | LOC105372582 | LOC105372592 | LOC105372596 | LOC105372606 | LOC105372630 | LOC105372631 | LOC105372639 | LOC105372646 | LOC105372649 | LOC105372664 | LOC105372666 | LOC105372667